PPPK-DHPS: Dihydropteroate synthetase
A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.
Protein in Plasmodium falciparum that 2 drugs act on.
- Drugs that act on it: 2
- Approved: 2
- In phases 1 to 3: 0
- Sponsors: 1
- Organism: Plasmodium falciparum
Who Is On It, and How Far Along
Every drug ChEMBL records acting on PPPK-DHPS, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule
The Landscape
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.| Sulfadoxine | Approved | — | Small molecule | Inhibitor | Dihydropteroate synthetase inhibitor | 7 | — |
| Sulfacytine | Approved | Glenwood | Small molecule | Inhibitor | Dihydropteroate synthetase inhibitor | 0 | — |
Open Trials
The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 7 in all, from ClinicalTrials.gov.Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2013, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. ChEMBL and Open Targets